Joint Technology Initiative (JTI) - Innovative Medicines Initiative (IMI)

JTIs are a new form of public-private R&D partnerships, fostering research in any specific sector requiring the mobilization of huge public and private resources and investments, so that ambitious large-scale goals may be achieved. The JTI IMI (Innovative Medicines Initiative) is managed by a Joint Undertaking between the European Commission, a pharmaceutical industry association represented by EFPIA (The European Federation of Pharmaceutical Industries and Associations), and IMI member organizations. IMI stems from the European Technology Platform of the same name under the Sixth Framework Programme.

The JTI IMI provides new technologies and instruments aiming at speeding up  the development of more efficient and safer medicines, overcoming the typical bottlenecks of pre-competitive research during the drug development process. Research is mainly focused on the development and testing of new techniques and approaches allowing to achieve a higher level of reliability in terms of safety and efficacy of the newly drugs.

Set up in 2007, the JTI IMI manages a € 2 billion budget, of which € 1 billion is contributed by the European Commission’s Seventh Framework Programme and € 1 billion are in-kind contributions from member companies of EFPIA.